protein that aggregates to form amyloid fibrils. These the apolipoprotein A-II gene. proteins may be the result of single nucleotide change, Background. Although apolipoprotein A-II (apoA-II) asso-Case report autosomal-dominant disease, amyloid fibril formation, lipoprotein, glomerulosclerosis.
deletion or insertion in the gene coding for the amyloid ciated amyloidosis has been described in the senescent accelerprecursor protein. To date, hereditary amyloidosis has ated mouse (SAM) model of aging, so far there has been no been associated with over 70 mutations in TTR, 9 mutareport of human apoA-II amyloidosis except for a recent report of renal amyloidosis resulting from a stop-codon to glycine tions in apoA-I, 4 in fibrinogen A␣-chain, 2 in lysozyme, mutation of apoA-II. The mechanisms of amyloid formation 2 in gelsolin, and 1 in cystatin C [7] . Apolipoprotein A-II in human apoA-II amyloidosis are not clear.
(apoA-II) is one of the major components of plasma Methods. A 46-year-old Caucasian male with proteinuria high-density lipoprotein (HDL) and is mainly produced noted at 42 years of age was studied. Renal biopsy revealed amyloid deposition in glomeruli. DNA analysis of genes known in the liver and small intestine with N-terminus pre-and to be associated with hereditary renal amyloidosis revealed no pro-peptides. Mature apoA-II is composed of 77 amino abnormalities. To elucidate the type of his amyloidosis, apoAacid residues and, in plasma, exists mainly as a disulfide-II gene and plasma apoA-II were examined. linked dimer with a molecular weight of approximately Results. DNA analysis revealed heterozygosity for a G to 17 kD [8] . While apoA-II was well known to form amy-C transversion at the second position of the stop-codon of apoA-II gene, suggesting a stop to serine substitution at codon loid fibrils in the senescence accelerated mouse (SAM) 78 . Western blot analysis and amino acid sequence analysis of model of aging [9] , apoA-II amyloidosis had never been the patient's plasma apoA-II showed both normal apoA-II and reported in humans. Moreover, no mutant human apoAvariant apoA-II with a 21-amino acid residue extension at the II proteins have been described. Recently, Benson et al C-terminus.
Conclusions. These results indicate that the patient's amy-identified a novel type of amyloid composed of a variant loid fibrils were derived from apoA-II and the amyloidogenesis apoA-II isolated from kidney of an affected patient in is likely to be closely linked to the peptide extension at the a kindred originally reported in 1973 [10, 11] . Although C-terminus of variant apoA-II. The pathogenesis of human the causative relationship between the mutant apoA-II apoA-II amyloidosis is different from that of SAM. and amyloid fibril formation has been recognized, there have been no other reports of human apoA-II amy-Hereditary systemic amyloidosis may be caused by loidosis. The mechanisms of amyloid fibril formation mutations in a number of plasma proteins including transfrom apoA-II and similarities or differences between thyretin (TTR), cystatin C, apolipoprotein A-I (apoA-I), human and SAM have not been addressed. gelsolin, fibrinogen A␣-chain, and lysozyme [1] [2] [3] [4] [5] [6] . Each
This study reports a patient with renal amyloidosis type of amyloidosis is inherited as an autosomal-domiwho has a novel variant of apoA-II, and discusses possinant disease and is associated with a structurally altered ble mechanisms of amyloid formation from variant apoA-II.
of approximately 40% of glomeruli and amyloid deposition in glomeruli ( Fig. 1A ). Amyloid deposits also were  2001 by the International Society of Nephrology present in the walls of medium-sized blood vessels (Fig. DNA studies searching for mutations in genes known 1B); Significant past history was a serum creatinine deterto be associated with systemic amyloidosis including mination of 1.3 mg/dL at age 35. An abdominal fat pad TTR, apoA-I, lysozyme and fibrinogen A␣-chain failed aspirate was positive for amyloid deposition, and amyto reveal any abnormalities. loid was noted in blood vessel walls of a bone marrow Subsequently, the patient has continued to work withbiopsy. There were no signs of neuropathy, cardiomegout medical problems except for hypertension that has aly, or hepato-splenomegaly on physical examination. been controlled medically. Family history revealed that the patient's mother died at age 67 of cancer of the breast, and the father died at METHODS age 75 of cancer of the urinary bladder. One sister and DNA isolation three half siblings were reported to be in good health.
Genomic DNA was isolated from peripheral blood The patient's two children, ages four years and eight leukocytes using a standard phenol/chloroform method. months, were well. Evaluation for systemic amyloidosis revealed normal electrocardiogram and echocardio-Single-strand conformation polymorphism analysis gram. There was no evidence of monoclonal gammopa-Exons 3 and 4 of the apoA-II gene were examined by thy on immunofixation of serum or urine. There was single-strand conformation polymorphism (SSCP) anonly modest proteinuria (595 mg/24 h), and creatinine clearance was 47 mL/min. alysis using oligonucleotide primers as follows: exon 3, (A2E3F) TGC TGT GGA CCC AGC TGA and 4 (yielding a 161 bp product). After purification of PCR products by QIAquick PCR purification kit (Qiagen), (A2E3R) GAA CCC CTT GCC CTG AGA yielding a 217 bp product; exon 4, (A2E4F) CTA ATC CCC TCA 12.5 L of amplified DNA was added to 1 L of NlaIII (New England Biolabs, Beverly, MA, USA), 1.6 L of CCT A and (A2E4R) GGA AGA CAA TGG TCT G yielding a 161 bp product. Polymerase chain reaction its specific buffer, 0.16 L of 100 ϫ bovine serum albumin (BSA) and 0.74 L of distilled water, and incubated for (PCR) was done in a total volume of 50 L, containing 5 L of 10 ϫ PCR buffer (100 mmol/L Tris-HCl, pH three hours at 37ЊC. The samples were electrophoresed through 3% (wt/vol) Nusieve GTG agarose gel (FMC 8.3, 500 mmol/L KCl, 12 mmol/L MgCl 2 ), 8 L of 1.25 mmol/L dNTP, 15 pmol of each primer, 2.5 units of Taq BioProducts, Rockland, ME, USA), stained with ethidium bromide and photographed under ultraviolet light. polymerase (Sigma, St. Louis, MO, USA) and 100 ng of genomic DNA. Amplification was performed using a Western blot analysis of plasma Perkin-Elmer Thermal Cycler (Norwalk, CT, USA) for 40 cycles consisting of denaturing at 95ЊC for 30 seconds, Plasma samples in sodium dodecyl sulfate (SDS) buffer were heated in a boiling water bath for 10 minutes annealing at 63ЊC (exon 3) or 60ЊC (exon 4) for one minute, and extension at 72ЊC for 30 seconds. Six micro-with or without 5% 2-mercaptoethanol and electrophoresed on a 16.5% Tris-Tricine Ready gel (Bio-Rad, Her-liters of polymerase chain reaction (PCR) product was diluted in 20 L of SSCP buffer containing 98% for-cules, CA, USA) for two hours at 100 V. Subsequently, proteins were transferred for one hour at 90 V onto nitro-mamide, 0.05% xylene cyanol FF, 0.05% bromophenol blue, 10 mmol/L NaOH and 10 mmol/L ethylenedi-cellulose membrane (Trans-Blot Transfer Medium; Bio-Rad). After blocking the membrane with 5% nonfat aminetetraacetic acid (EDTA), and heated at 95ЊC for five minutes. Six microliters of diluted samples was elec-dry milk in phosphate-buffered saline (PBS), pH 7.4, the apoA-II bands were detected with sheep anti-human trophoresed on a 15% polyacrylamide gel including 10% glycerol in the Tris-glycine buffer, pH 8.3. Single-apoA-II (1:1000 in 5% milk; Boehringer Mannheim, Mannheim, Germany). Alkaline phosphatase-conjugated stranded PCR products were visualized by silver staining [12] .
donkey anti-sheep IgG (Sigma) was used as the second antibody (1:1000 in 5% milk). The immunoblots were Direct DNA sequence analysis visualized with a reaction to NBT/BCIP Alkaline phosphatase substrate (Sigma). DNA was analyzed by the direct sequencing of exons 3 and 4 of the apoA-II gene. PCR was done as indicated Isolation of plasma apoA-II and amino acid in the last section of this article. The PCR product was sequence analysis purified by QIAquick PCR purification kit (Qiagen, Valencia, CA, USA) according to the manufacturer's proto-Plasma apoA-II was isolated according to a method to isolate high density lipoprotein (HDL) described pre-col. Sequencing reaction was performed by using 1.0 L of purified PCR-product as the template and the Thermo viously with some modifications [15] . Five milliliters of plasma was adjusted to a density of 1.21 g/mL with KBr Sequence [␣-33 P]ddNTP radiolabeled terminator cycle sequencing kit (USB, Cleveland, OH, USA). Samples and ultracentrifuged at 100,000 rpm for six hours (TL-100 ultracentrifuge; Beckman, Palo Alto, CA, USA). were electrophoresed on a 6% polyacrylamide gel at 45 W for three hours using a glycerol tolerant gel buffer,
The top layer was collected, dialyzed against distilled water, and lyophilized. The sample was dissolved in 8 dried and exposed to Kodak X-Omat film (Eastman Kodak, Rochester, NY, USA). mol/L guanidine HCl containing dithiothreitol (DTT), alkylated with iodoacetic acid, and fractionated on a Restriction fragment length polymorphism Sepharose CL6B column (Pharmacia, Uppsala, Swe-(RFLP) analysis den). Fractions were combined into three pools according to the absorbance at 280 nm, dialyzed against In the absence of a spontaneous creation of an endonuclease restriction site by the TGA to TCA mutation in distilled water, and lyophilized. Protein samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel the stop codon of the apoA-II gene, a PCR-induced mutation restriction analysis (IMRA) was performed electrophoresis (SDS-PAGE) and Western blot using anti-human apolipoprotein A-II antibody (Boehringer [13]. A mutation primer (A2S78) corresponding to nucleotides 2151 to 2129 of the apoA-II nucleotide sequence Mannheim) as indicated previously in this article. The Sepharose CL6B pool III was digested with trypsin and [14] with an A instead of T at the second position from the 3Ј end (5Ј-GGA AGA CAA TGG TCT GGA CAC the resulting peptides were fractionated on a Beckman Ultrasphere-ODS high-pressure liquid chromatography AT-3Ј) was used to create a restriction site for NlaIII (CATG) only in the mutant gene PCR products. PCR (HPLC) column. Samples were subjected to Edman degradation on an ABI 473A protein sequencer using the was performed with A2E4F and A2S78 primers under the same conditions as in the DNA sequencing of exon manufacturer's standard cycle programs. 
RESULTS

DNA analysis
The SSCP analysis revealed an abnormally migrating band for apoA-II exon 4 PCR products of the patient in contrast to those of normal controls (data not shown). Direct DNA sequencing of the exon 4 PCR product showed a single base substitution in the stop codon for the apoA-II gene (TGA to TCA) indicating a stop to serine substitution at codon 78 followed by 60 bases before a new stop codon (Fig. 2) [14] . No other mutations were found in exons 3 and 4 of apoA-II gene, which encode the entire pro-and mature apoA-II protein, in revealed that the patient had the NlaIII recognition site bp (the latter is not visible) for the mutant allele. The PCR-amplified fragment (161 bp) of the patient (lane 3) was incompletely digested, associated with the guanine to cytosine mutation at the indicating that he is heterozygous for this mutation. The fragments second position of the stop codon ( Fig. 3 ). Electrophorefrom two normal controls were not digested with NlaIII (lanes 1 and sis of the digested PCR product in the patient gave a 2). M, 100 bp molecular ruler DNA size standard (Bio-Rad). digestion band of 137 bp in addition to the normal 161 bp band indicating heterozygosity for this mutation. To exclude the possibility that the G to C mutation might apoA-II ( Fig. 4 ). In the patient in this study, positive be a polymorphism, we analyzed DNA from 50 unrelated bands migrating with molecular weight corresponding individuals (100 alleles). None had the G to C mutation.
to dimeric normal apoA-II, heterodimeric apoA-II with Characterization of plasma apoA-II normal and variant molecules, and dimeric variant apoA-II were identified in nonreducing conditions. In the pres-Plasma samples obtained from this patient, a patient ence of reducing conditions, Western analysis revealed with variant apoA-II (stop to glycine mutation of apoAtwo bands (ϳ8 and 10 kD) corresponding to normal II) described previously [10] , and a normal individual were studied by Western blot analysis using anti-human apoA-II monomer and the larger variant apoA-II mono-these patients varied from adolescence to the fifth decade and they died in the fifth to sixth decades. While autopsy studies revealed that amyloid accumulation was present in most visceral organs, except for central nervous system and peripheral nerves, renal amyloid was the most prominent feature [11] . The severity of amyloid deposition in the liver, heart, and spleen was moderate and limited mainly to vascular walls. Benson et al isolated the amyloid fibrils from the kidney obtained from an autopsied patient in that family and identified that the amyloid fibrils were derived from variant apoA-II caused by a stop codon mutation (TGA; stop to GGA; glycine) [10]. This mutation results in a 21-amino acid residue extension at the C-terminus of normal apoA-II protein.
In the present study, DNA analysis revealed that the II, but also variant apoA-II with a 21-residue extension at the C-terminus. This 21-amino acid extension was completely identical to that in the patient with variant mer, respectively. These results were consistent with apoA-II described by Benson et al, except for serine at those in the patient with stop to glycine mutation of residue 78 [10]. apoA-II [10] . Those extra bands were not detected in a
The clinical picture of the patient described here renormal individual.
sembles that in patients with variant apoA-II reported The top layer of the patient's plasma after being adpreviously [10, 11] . During the clinical course, the justed to a density of 1.21 g/mL and ultracentrifugation most noticeable clinical manifestation was nephropathy was dissolved in 8 mol/L guanidine HCl in the presence caused by renal amyloidosis in both the patient described of DTT, alkylated with iodoacetic acid, and fractionated and the patients with stop to glycine mutation in the on a Sepharose CL6B column (Fig. 5 ). While two major apoA-II gene. Moreover, the distinctive feature of amyretarded peaks (pools II and III) were found, SDSloidosis in both families is that affected individuals do PAGE analysis and Western blot analysis indicated that not have significant dysfunction of other visceral organs, most normal and variant apoA-II were contained in pool including the heart, liver, and peripheral nerves due to III (Fig. 6 ). Amino acid sequence analysis of pool III amyloid deposition, although amyloid accumulation was after tryptic digestion showed that both normal apoAseen systemically in affected patients of both families. II and variant apoA-II, with serine at position 78 and a While the mechanism of how amyloid proteins have or-20 amino acid extension, were present (Fig. 7 ). The N-tergan specificity that leads to variation in clinical features is minal residues 1-3 tryptic peptide was not detected, since unknown, the non-neuropathic, nephropathic syndrome N-terminal glutamine is cyclized to pyroglutamate and seems to be the prominent feature for apoA-II amyblocked to Edman analysis. This result confirmed the loidosis. The clinical features in both kindreds are similar findings of DNA sequence analysis.
to fibrinogen A␣-chain and lysozyme amyloidosis in terms of nephropathy without neuropathy [5, 6, 17] . Al-DISCUSSION though there is no clear difference in the onset of amyloidosis among apoA-II, fibrinogen A␣-chain, and lyso-Recently, human apoA-II amyloidosis was first identizyme amyloidosis, the latter forms (fibrinogen A␣-chain fied in an affected member of a family originally reported and lysozyme) usually show more extensive hepatic and in 1973 as an unusual form of hereditary nonneuropathic splenic involvement. amyloidosis [11], similar to that described by Ostertag
Despite recent biochemical and molecular-genetic ad- [16] . Clinically, the most prominent manifestation in all vances, possible mechanisms of amyloid fibril formation affected patients of that family was renal failure characin apoA-II amyloidosis are not clear. In comparison with terized by proteinuria, edema, hypertension, and azotethe previously reported family with variant apoA-II mia. Symptoms caused by amyloidosis of other visceral (stop to glycine mutation) [10, 11] , the affected patients organs including the heart, liver, spleen, and peripheral nerves were absent [10, 11] . The onset of the disease in in both families have a novel 21-amino acid peptide in to HDL caused by variant apoA-II with extended sequence without lipid-binding capability could alter its metabolism and accelerate amyloid fibril formation [10]. The same thing may be hypothesized for amyloid fibril formation in variant apoA-II with stop to serine mutation in this study, although the precise conformational change with both types of variant apoA-II (stop to glycine and stop to serine mutation) has not been fully understood.
Higuchi et al suggested importance of amino acid substitution in the N-terminal region of apoA-II for development of amyloid in the SAM, since the strain of mouse (SAMP) with the highest incidence of amyloidosis has a glutamine for proline substitution at the fifth residue from the N-terminus of apoA-II [23, 24] . However, hu- ilies did not have a mutation at the fifth residue. Therefore, it is unlikely in the human that the N-terminal structure of the molecule plays an important role in its tendency to form amyloid fibrils [10] . Also, in human common, although the first residue of that 21-residue apoA-II amyloid patients, deposited amyloid fibrils peptide (glycine or serine) is different. To date, there are composed of only full-length variant apoA-II [10], have not been reports of human apoA-II amyloidosis whereas mature apoA-II and pro-apoA-II were detected caused by other mutations except for the stop-codon in amyloid fibrils of SAM [25] . In addition, heavy amysite. It is likely, therefore, that the role of human apoAloid deposition is seen in the liver, spleen, and heart as II as a precursor of amyloid fibrils is closely related to well as the kidney in SAM [26] . Hence, the pathogenesis the extension of the protein at the C-terminus. Similar of apoA-II related-amyloid formation in human is likely cases of amyloid fibril formation caused by novel peptide to differ from amyloid formation in the SAM model. sequences at the C-terminus have been identified with
In the present study, the patient had no family history fibrinogen A␣-chain [18, 19] , ABri in familial British of amyloidosis. Since DNA for analysis was limited to dementia [20] , and ADan in familial Danish dementia only the patient, it could not be determined whether [21] . some asymptomatic carriers exist in this family or this The new peptide sequence at the C-terminus in variant stop to serine mutation was caused by de novo mutation. apoA-II with stop to glycine mutation is predicted to
In the apoA-II amyloidosis family recently reported, the contain an ␣-helix that is different from the three class amyloid showed autosomal dominant inheritance [10], A amphipathic helices, important for lipid binding [22]. Benson et al emphasized that decreased binding capacity similar to all other types of hereditary amyloidosis [7] .
